Stock-Based Compensation - Additional Information (Details)				1 Months Ended			3 Months Ended				9 Months Ended
	Nov. 18, 2020 USD ($) grantee shares	Apr. 22, 2020 USD ($) grantee shares	Jun. 22, 2019 shares	Jun. 30, 2025 shares	Jun. 30, 2024 shares	Dec. 31, 2023 USD ($) trading_day shares	Sep. 30, 2025 USD ($) $ / shares shares	Mar. 31, 2025 USD ($) shares	Sep. 30, 2024 USD ($) shares	Mar. 31, 2024 USD ($) shares	Sep. 30, 2025 USD ($) $ / shares shares	Sep. 30, 2024 USD ($) shares	Dec. 31, 2024 $ / shares shares	Nov. 30, 2023 shares	Dec. 31, 2021 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation							$ 35,264,000		$ 27,131,000		$ 101,992,000	$ 77,432,000
Stock-based compensation expense, capitalized to inventory							900,000				$ 2,800,000
Weighted-average grand date fair value of options granted (in dollars per share) \| $ / shares											$ 30.15
Total intrinsic value of options exercised											$ 18,200,000
Issuance of common stock under employee stock purchase plan (ESPP)							$ 3,177,000	$ 3,237,000	$ 2,138,000	$ 2,364,000
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of common stock under employee stock purchase plan ESPP (in shares) \| shares							105,325	156,097	100,794	93,344
A&R 2019 Plan \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares reserved for future issuance (in shares) \| shares						3,750,000								2,000,000
2021 A&R Plan \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares reserved for future issuance (in shares) \| shares							10,350,398				10,350,398
Increase (decrease) in common shares reserved for future issuance (in shares) \| shares				5,000,000	6,500,000
A&R 2019 Inducement Plan \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares reserved for future issuance (in shares) \| shares							783,507				783,507
Eidos Awards Exchange \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common shares reserved for future issuance (in shares) \| shares															2,802,644
2020 Stock and Equity Award Exchange Program
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of grantees \| grantee	16	149
Maximum potential milestone performance-based awards to be settled in fully-vested RSA	$ 11,700,000	$ 183,400,000
Share-based payment arrangement, expensed and capitalized (reversals)							$ 0		$ 0		$ 0	(8,700,000)
2020 Stock and Equity Award Exchange Program \| Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, shares issued in period (in shares) \| shares	24,924	554,064
2019 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation							$ 900,000		600,000		$ 2,300,000	$ 1,700,000
Common shares reserved for future issuance (in shares) \| shares							3,100,352				3,100,352
Weighted-average grand date fair value of options granted (in dollars per share) \| $ / shares											$ 13.04
Expected volatility, minimum											46.70%
Expected volatility, maximum											60.90%
Risk-free interest rate, minimum											4.10%
Risk-free interest rate, maximum											5.00%
Dividend yield											0.00%
Expected term (in years)											6 months
Number of common shares authorized to issue for issuance of awards (in shares) \| shares			2,000,000
Percentage of automatic annual increase in number of shares reserved for future issuance			1.00%
Purchase price as percentage of lower of fair market value as of beginning or end of offering period			85.00%
Offering period			6 months
Maximum percentage of employee payroll deduction for stock purchase			15.00%
Maximum number of shares eligible to purchase during offering period (in shares) \| shares			3,500
Issuance of common stock under employee stock purchase plan ESPP (in shares) \| shares											261,422	194,138
Issuance of common stock under employee stock purchase plan (ESPP)											$ 6,400,000	$ 4,500,000
Performance-Based Milestone Awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation							$ 0		0		3,600,000	11,800,000
Share-based payment arrangement, expense, probable achievement of milestones							300,000		500,000		700,000	1,400,000
Share-based payment arrangement, expense, probable achievement of milestones, reversal												1,600,000
Performance-Based Milestone Awards \| 2020 Stock and Equity Award Exchange Program
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based payment arrangement, nonvested award, cost not yet recognized, amount	$ 0	$ 17,400,000
Performance-Based Milestone Awards \| 2020 Stock and Equity Award Exchange Program \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost, period for recognition		8 months 12 days
Performance-Based Milestone Awards \| 2020 Stock and Equity Award Exchange Program \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized compensation cost, period for recognition		1 year 8 months 12 days
Share-Based Payment Arrangement, Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation							3,900,000		5,200,000		$ 12,500,000	17,400,000
Unrecognized compensation cost, period for recognition											1 year 6 months
Weighted-average grand date fair value of options granted (in dollars per share) \| $ / shares											$ 30.15
Unrecognized compensation cost							$ 15,100,000				$ 15,100,000
Expected volatility, minimum											94.00%
Expected volatility, maximum											94.70%
Dividend yield											0.00%
Expected term (in years)											6 years
Share-Based Payment Arrangement, Option \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period											3 years
Share-Based Payment Arrangement, Option \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period											4 years
Share-Based Payment Arrangement, Option \| 2020 Stock and Equity Award Exchange Program
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, shares issued in period (in shares) \| shares	70,436	1,268,110
Restricted Stock Awards \| 2020 Stock and Equity Award Exchange Program
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, shares issued in period (in shares) \| shares		50,145
Performance Based Restricted Stock Awards \| 2020 Stock and Equity Award Exchange Program
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, shares issued in period (in shares) \| shares		22,611
Performance-Based Stock Options \| 2020 Stock and Equity Award Exchange Program
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, shares issued in period (in shares) \| shares	10,772
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested shares of restricted stock outstanding (in shares) \| shares							10,694,969				10,694,969		10,272,798
Weighted average grant date fair value (in dollars per share) \| $ / shares							$ 26.72				$ 26.72		$ 21.91
Restricted Stock Units (RSUs) \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period											2 years
Restricted Stock Units (RSUs) \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, award vesting period											4 years
Performance-Based RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation							$ 700,000				$ 1,500,000
Unrecognized compensation cost, period for recognition											1 year 10 months 24 days
Unvested shares of restricted stock outstanding (in shares) \| shares							194,943				194,943
Weighted average grant date fair value (in dollars per share) \| $ / shares							$ 33.75				$ 33.75
Unrecognized compensation cost							$ 5,100,000				$ 5,100,000
Market-Based Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation							$ 500,000		$ 1,700,000		$ 2,500,000	$ 6,500,000
Unvested shares of restricted stock outstanding (in shares) \| shares							375,000				375,000
Weighted average grant date fair value (in dollars per share) \| $ / shares							$ 28.73				$ 28.73
Unrecognized compensation cost							$ 0				$ 0
Share-based payment arrangement, consecutive trading days \| trading_day						20
Share-based payment arrangement, performance period from date of grant						6 years
Grant-date fair value of RSUs						$ 10,800,000
Expected volatility, minimum						96.80%
Expected volatility, maximum						113.70%
Risk-free interest rate, minimum						4.22%
Risk-free interest rate, maximum						4.35%
Dividend yield						0.00%
Market-Based Restricted Stock Units (RSUs) \| Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)						3 years
Market-Based Restricted Stock Units (RSUs) \| Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)						6 years

BridgeBio Pharma, Inc. 10-Q